Telemedicine and cystic fibrosis: Do we still need face-to-face clinics?

E. Dixon; K. Dick; S. Ollosson; D. Jones; H. Mattock; S. Bentley; C. Saunders; J Matthews; B. Dobra; J. King; C. Edmondson; J. C. Davies

doi:10.1016/j.prrv.2021.05.002

Telemedicine and cystic fibrosis: Do we still need face-to-face clinics?

E. Dixon, K. Dick, S. Ollosson, D. Jones, H. Mattock, S. Bentley, C. Saunders, J Matthews, B. Dobra, J. King, C. Edmondson, J. C. Davies

Department of Psychology

Research output: Contribution to journal › Review article › peer-review

38 Citations (SciVal)

84 Downloads (Pure)

Abstract

There has been growing interest in telemedicine for cystic fibrosis over recent years based largely on convenience for patients and/or increasing the frequency of surveillance and early detection which, it is assumed, could improve treatment outcomes. During 2020, the covid-19 pandemic catalysed the pace of development of this field, as CF patients were presumed to be at high risk of infection. Most clinics adapted to digital platforms with provision of lung function monitoring and sample collection systems. Here, we present the views of multidisciplinary team members at a large paediatric CF centre on what has worked well and what requires further optimisation in the future. In response to the question posed, ‘Do we still need face to face clinics?’ our answer is ‘Yes, but not every time, and not for everyone’.

Original language	English
Pages (from-to)	23-28
Number of pages	6
Journal	Paediatric Respiratory Reviews
Volume	42
Early online date	19 May 2021
DOIs	https://doi.org/10.1016/j.prrv.2021.05.002
Publication status	Published - 1 Jun 2022

Bibliographical note

Funding Information:
The authors wish to recognise contributions from the Royal Brompton & Harefield Hospitals Charity for assistance with equipment funding and patient travel during the coronavirus pandemic. Research at the site is supported by the Cystic Fibrosis Trust and by the National Institutes of Health Research through the Imperial Biomedical Research Centre, the Royal Brompton/NHLI Clinical Research Facility and a Senior Investigator Award (JCD). Prof. Jane Davies has performed clinical trial leadership roles, educational and/ or advisory activities for the following: Abbvie, Algipharma AS, Bayer AG, Boehringer Ingelheim Pharma GmbH & Co. KG, Eloxx, Enterprise, Galapagos NV, ImevaX GmbH, Ionis, Nivalis Therapeutics, Inc. Novartis, ProQR Therapeutics III B.V. Proteostasis Therapeutics, INC. Pulmocide Raptor Pharmaceuticals, Inc, Vertex Pharmaceuticals. The other authors have no disclosures of interest.

Funding Information:
The authors wish to recognise contributions from the Royal Brompton & Harefield Hospitals Charity for assistance with equipment funding and patient travel during the coronavirus pandemic. Research at the site is supported by the Cystic Fibrosis Trust and by the National Institutes of Health Research through the Imperial Biomedical Research Centre, the Royal Brompton/NHLI Clinical Research Facility and a Senior Investigator Award (JCD).

Publisher Copyright:
© 2021 Elsevier Ltd

Keywords

Cystic fibrosis
Home monitoring
Lung function
Physiotherapy
Psychology
Remote care
Spirometry
Telehealth
Telemedicine

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Pulmonary and Respiratory Medicine

Access to Document

10.1016/j.prrv.2021.05.002

Accepted Manuscript TeleAccepted author manuscript, 342 KBLicence: CC BY-NC-ND

Cite this

@article{b8fe7a6551f64d28bc3e2432db73a61e,

title = "Telemedicine and cystic fibrosis: Do we still need face-to-face clinics?",

abstract = "There has been growing interest in telemedicine for cystic fibrosis over recent years based largely on convenience for patients and/or increasing the frequency of surveillance and early detection which, it is assumed, could improve treatment outcomes. During 2020, the covid-19 pandemic catalysed the pace of development of this field, as CF patients were presumed to be at high risk of infection. Most clinics adapted to digital platforms with provision of lung function monitoring and sample collection systems. Here, we present the views of multidisciplinary team members at a large paediatric CF centre on what has worked well and what requires further optimisation in the future. In response to the question posed, {\textquoteleft}Do we still need face to face clinics?{\textquoteright} our answer is {\textquoteleft}Yes, but not every time, and not for everyone{\textquoteright}.",

keywords = "Cystic fibrosis, Home monitoring, Lung function, Physiotherapy, Psychology, Remote care, Spirometry, Telehealth, Telemedicine",

author = "E. Dixon and K. Dick and S. Ollosson and D. Jones and H. Mattock and S. Bentley and C. Saunders and J Matthews and B. Dobra and J. King and C. Edmondson and Davies, {J. C.}",

note = "Funding Information: The authors wish to recognise contributions from the Royal Brompton & Harefield Hospitals Charity for assistance with equipment funding and patient travel during the coronavirus pandemic. Research at the site is supported by the Cystic Fibrosis Trust and by the National Institutes of Health Research through the Imperial Biomedical Research Centre, the Royal Brompton/NHLI Clinical Research Facility and a Senior Investigator Award (JCD). Prof. Jane Davies has performed clinical trial leadership roles, educational and/ or advisory activities for the following: Abbvie, Algipharma AS, Bayer AG, Boehringer Ingelheim Pharma GmbH & Co. KG, Eloxx, Enterprise, Galapagos NV, ImevaX GmbH, Ionis, Nivalis Therapeutics, Inc. Novartis, ProQR Therapeutics III B.V. Proteostasis Therapeutics, INC. Pulmocide Raptor Pharmaceuticals, Inc, Vertex Pharmaceuticals. The other authors have no disclosures of interest. Funding Information: The authors wish to recognise contributions from the Royal Brompton & Harefield Hospitals Charity for assistance with equipment funding and patient travel during the coronavirus pandemic. Research at the site is supported by the Cystic Fibrosis Trust and by the National Institutes of Health Research through the Imperial Biomedical Research Centre, the Royal Brompton/NHLI Clinical Research Facility and a Senior Investigator Award (JCD). Publisher Copyright: {\textcopyright} 2021 Elsevier Ltd",

year = "2022",

month = jun,

day = "1",

doi = "10.1016/j.prrv.2021.05.002",

language = "English",

volume = "42",

pages = "23--28",

journal = "Paediatric Respiratory Reviews",

issn = "1526-0542",

publisher = "Elsevier",

}

TY - JOUR

T1 - Telemedicine and cystic fibrosis

T2 - Do we still need face-to-face clinics?

AU - Dixon, E.

AU - Dick, K.

AU - Ollosson, S.

AU - Jones, D.

AU - Mattock, H.

AU - Bentley, S.

AU - Saunders, C.

AU - Matthews, J

AU - Dobra, B.

AU - King, J.

AU - Edmondson, C.

AU - Davies, J. C.

N1 - Funding Information: The authors wish to recognise contributions from the Royal Brompton & Harefield Hospitals Charity for assistance with equipment funding and patient travel during the coronavirus pandemic. Research at the site is supported by the Cystic Fibrosis Trust and by the National Institutes of Health Research through the Imperial Biomedical Research Centre, the Royal Brompton/NHLI Clinical Research Facility and a Senior Investigator Award (JCD). Prof. Jane Davies has performed clinical trial leadership roles, educational and/ or advisory activities for the following: Abbvie, Algipharma AS, Bayer AG, Boehringer Ingelheim Pharma GmbH & Co. KG, Eloxx, Enterprise, Galapagos NV, ImevaX GmbH, Ionis, Nivalis Therapeutics, Inc. Novartis, ProQR Therapeutics III B.V. Proteostasis Therapeutics, INC. Pulmocide Raptor Pharmaceuticals, Inc, Vertex Pharmaceuticals. The other authors have no disclosures of interest. Funding Information: The authors wish to recognise contributions from the Royal Brompton & Harefield Hospitals Charity for assistance with equipment funding and patient travel during the coronavirus pandemic. Research at the site is supported by the Cystic Fibrosis Trust and by the National Institutes of Health Research through the Imperial Biomedical Research Centre, the Royal Brompton/NHLI Clinical Research Facility and a Senior Investigator Award (JCD). Publisher Copyright: © 2021 Elsevier Ltd

PY - 2022/6/1

Y1 - 2022/6/1

N2 - There has been growing interest in telemedicine for cystic fibrosis over recent years based largely on convenience for patients and/or increasing the frequency of surveillance and early detection which, it is assumed, could improve treatment outcomes. During 2020, the covid-19 pandemic catalysed the pace of development of this field, as CF patients were presumed to be at high risk of infection. Most clinics adapted to digital platforms with provision of lung function monitoring and sample collection systems. Here, we present the views of multidisciplinary team members at a large paediatric CF centre on what has worked well and what requires further optimisation in the future. In response to the question posed, ‘Do we still need face to face clinics?’ our answer is ‘Yes, but not every time, and not for everyone’.

AB - There has been growing interest in telemedicine for cystic fibrosis over recent years based largely on convenience for patients and/or increasing the frequency of surveillance and early detection which, it is assumed, could improve treatment outcomes. During 2020, the covid-19 pandemic catalysed the pace of development of this field, as CF patients were presumed to be at high risk of infection. Most clinics adapted to digital platforms with provision of lung function monitoring and sample collection systems. Here, we present the views of multidisciplinary team members at a large paediatric CF centre on what has worked well and what requires further optimisation in the future. In response to the question posed, ‘Do we still need face to face clinics?’ our answer is ‘Yes, but not every time, and not for everyone’.

KW - Cystic fibrosis

KW - Home monitoring

KW - Lung function

KW - Physiotherapy

KW - Psychology

KW - Remote care

KW - Spirometry

KW - Telehealth

KW - Telemedicine

UR - http://www.scopus.com/inward/record.url?scp=85103286469&partnerID=8YFLogxK

U2 - 10.1016/j.prrv.2021.05.002

DO - 10.1016/j.prrv.2021.05.002

M3 - Review article

C2 - 34215541

AN - SCOPUS:85103286469

SN - 1526-0542

VL - 42

SP - 23

EP - 28

JO - Paediatric Respiratory Reviews

JF - Paediatric Respiratory Reviews

ER -

Telemedicine and cystic fibrosis: Do we still need face-to-face clinics?

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this